[68Ga]/ [131I]-IR199: \[68Ga\]/ \[131I\]-IR199, single dose
Study summary
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[68Ga\]/ \[131I\]-IR199 in patients with Claudin 18.2 positive gastric cancer and pancreatic cancer.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Informed consent must be obtained in writing from the subject, their legally authorized representative, or caregiver.
2. Age equal to or above 18 years old.
3. Histologically or cytologically confirmed gastric cancer or pancreatic cancer with Claudin 18.2 expression.
4. Must have ≥1 Claudin 18.2 positive lesions.
Exclusion Criteria:
1. Less than two weeks since the last treatment that could cause bone marrow suppression.
2. Known or suspected history of ≥3 grade renal and urinary system diseases.
3. Medical history of allergy, hypersensitivity reaction or intolerance to radioactive drugs.
Primary outcome measure(s)
Absorbed radiation dose (Gy) distribution in normal organs and tumors by quantitative SPECT/CT dosimetry — about 24 hours from time of injection, about 48 hours from time of injection and about 72 hours from time of injection Absorbed radiation dose (Gy) distribution in normal organs and tumors by quantitative SPECT/CT dosimetry
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.